Renal Cell Carcinoma (First-Line Advanced/Metastatic) | Decision Base | US | 2015
What Attributes Will Distinguish Emerging Therapies, According to Physicians and Payers?
Targeted therapies, particularly tyrosine kinase inhibitors (TKIs) that target angiogenesis, dominate the treatment of advanced/metastatic renal cell carcinoma (RCC) in the first line. While mTOR inhibitors such as temsirolimus (Pfizer’s Torisel) have expanded the treatment options for patients in this setting, especially those with poor-prognosis disease, RCC remains incurable, and most first-line patients relapse following treatment. Significant clinical and commercial opportunities remain for new therapies that can provide greater survival benefits than the currently available agents.
Related Market Assessment Reports
Report
Uterine Fibroids – Current Treatment – Treatment Algorithms: Claims Data Analysis – Uterine Fibroids (US)
Treatment for uterine fibroids includes pharmacological approaches and surgical procedures. NSAIDs help alleviate the pain but do not reduce the fibroids’ size. Progestins (e.g., norethindrone,…
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (Including IBS Without Diarrhea) (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is classified into three subtypes:…
Report
Kidney Transplant – Current Treatment – Treatment Algorithms: Claims Data Analysis – Kidney Transplant (US)
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, patients must…
Report
Amyotrophic Lateral Sclerosis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Amyotrophic lateral sclerosis (ALS) is a disorder of the central nervous system characterized by motor neuron degeneration. ALS causes progressive weakness and atrophy of the muscles and loss of…
